Compare MAGN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAGN | MYGN |
|---|---|---|
| Founded | 1864 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.8M | 625.5M |
| IPO Year | N/A | 1995 |
| Metric | MAGN | MYGN |
|---|---|---|
| Price | $14.51 | $6.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $18.00 | $11.82 |
| AVG Volume (30 Days) | 575.2K | ★ 923.3K |
| Earning Date | 02-05-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,204,000,000.00 | $825,300,000.00 |
| Revenue This Year | $5.74 | $0.08 |
| Revenue Next Year | $2.51 | $5.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.50 | 0.21 |
| 52 Week Low | $7.82 | $3.76 |
| 52 Week High | $23.19 | $15.47 |
| Indicator | MAGN | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 38.51 |
| Support Level | $14.03 | $6.40 |
| Resistance Level | $14.77 | $7.15 |
| Average True Range (ATR) | 0.58 | 0.30 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 33.90 | 10.80 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.